Drugs / OSU6162
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT05296356 | Oct 2021 → May 2026 overdue | bipolar depression | Göteborg University | Recruiting | No outcome recorded |
| Phase 2 | NCT03209830 | Sep 2017 → Sep 2019 | acquired aneurysmal subarachnoid hemorrhage | Oslo University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04127669 | Mar 2017 → Jan 2020 | stroke disorder | Arvid Carlsson Research AB | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05641623 Comparator | Apr 2022 → May 2026 overdue | depressive disorder | Göteborg University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OSU 6162 | “In trial protocol, OSU6162-HCl is shortened to OSU6162.” NCT04127669 ↗ |
| Route | Oral | “The dose is taken orally as one circular coated tablet of 15 mg” NCT04127669 ↗ |